This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Cramer's 'Mad Money' Recap: Capitalizing on Market Panic (Final)

Stocks in this article: CXWGEOHSICVODDDCRRCBEXC

Positive Cancer Trug Tests

In a second "Executive Decision" segment, Cramer sat down with Daniel Junius, president and CEO of ImmunoGen (IMGN), whose stock is up 63% since Cramer first highlighted the company in November 2009.

ImmunoGen recently received positive results for phase 2 testing of its T-DM1 targeted breast cancer treatment. Junius said that even in phase 1 testing he saw compelling results for the drug and he's very excited to now have phase two and even phase three studies now in progress.

Junius did admit however, the the Federal Food and Drug Administration is in a tough spot when approving new treatments. He said that T-DM1 was before the FDA a year ago and the agency declined to consider it based on study methodology. Junius said ImmunoGen and its partners hope to have the drug before the FDA again in 2012, with subsequent studies completing in 2014.

When asked whether T-DM1 is too expensive or could be used for other cancers, Junius said that he's not worried about the drug's cost, as it replaces an already expensive round of chemotherapy for patients. As for other indications for the drug, he said that there is some interest in possibly using T-DM1 for gastric cancers as well, but no commitments have been made.

Junius ended by saying that some studies are currently open to new patients.

Cramer continued his recommendation of ImmunoGen, saying the company continues to make great progress in the fight against cancer.

Lightning Round

Cramer was bullish on Henry Schein (HSIC), Vodafone Group (VOD), DuPont (DD), Carbo Ceramics (CRR), Core Labs (CLB) and Exelon (EXC).

He was bearish on Arch Coal (ACI), World Wrestling Entertainment (WWE) and Citigroup (C).

Diversified Portfolio

In his "No Huddle Offense" segment, Cramer once again pitched diversification for investors' portfolios. He said investors need a mix of recession stocks, best of breed names and high yielders in order to weather this market.

Cramer said a portfolio that included Procter & Gamble (PG) and Johnson & Johnson, along with Eaton (ETN) and DuPont, and AT&T (T) and Kinder Morgan Energy Partners (KMP) would give investors just what they're looking for.

Closing Comments

Cramer said he's not worried about reports that Apple (AAPL), a stock which he owns for his charitable trust, Action Alerts PLUS , is canceling some iPad orders. Cramer said investors shouldn't rely on a single analyst and he's not changing his opinion on Apple.

--Written by Scott Rutt in Washington, D.C.

To contact the writer of this article, click here: Scott Rutt.

To follow the writer on Twitter, go to http://twitter.com/scottrutt.

To submit a news tip, send an email to: tips@thestreet.com.

3 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,399.67 +19.26 0.12%
S&P 500 1,904.01 +17.25 0.91%
NASDAQ 4,316.0740 +57.6360 1.35%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs